These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 34831165)

  • 21. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
    Tahmasebi S; Elahi R; Esmaeilzadeh A
    Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma.
    Zhou S; Sun H; Choi SI; Yin J
    Front Biosci (Landmark Ed); 2023 Sep; 28(9):206. PubMed ID: 37796692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.
    Zhang X; Zhu L; Zhang H; Chen S; Xiao Y
    Front Immunol; 2022; 13():927153. PubMed ID: 35757715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
    Qu J; Mei Q; Chen L; Zhou J
    Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors.
    Donnadieu E; Dupré L; Pinho LG; Cotta-de-Almeida V
    J Leukoc Biol; 2020 Oct; 108(4):1067-1079. PubMed ID: 32620049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
    Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
    Front Immunol; 2022; 13():871661. PubMed ID: 35911706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment.
    Feldman L; Brown C; Badie B
    Neurosurgery; 2021 May; 88(6):1056-1064. PubMed ID: 33575786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers.
    Gotti M; Defrancesco I; D'Angelo M; Basso S; Crotto L; Marinelli A; Maccalli C; Iaconianni V
    Front Immunol; 2020; 11():565236. PubMed ID: 33193333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.
    Andrea AE; Chiron A; Mallah S; Bessoles S; Sarrabayrouse G; Hacein-Bey-Abina S
    Front Immunol; 2022; 13():830292. PubMed ID: 35211124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical utility of CAR T cell therapy in brain tumors: Lessons learned from the past, current evidence and the future stakes.
    Chatterjee A; Asija S; Yadav S; Purwar R; Goda JS
    Int Rev Immunol; 2022; 41(6):606-624. PubMed ID: 36191126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic potential of CAR T cell in malignancies: A scoping review.
    Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG
    Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis.
    Zhou H; Luo Y; Zhu S; Wang X; Zhao Y; Ou X; Zhang T; Ma X
    BMC Cancer; 2018 Sep; 18(1):929. PubMed ID: 30257649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current challenges and emerging opportunities of CAR-T cell therapies.
    Abreu TR; Fonseca NA; Gonçalves N; Moreira JN
    J Control Release; 2020 Mar; 319():246-261. PubMed ID: 31899268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CAR T-Cell Therapy for Cancer: Latest Updates and Challenges, with a Focus on B-Lymphoid Malignancies and Selected Solid Tumours.
    Tang HKC; Wang B; Tan HX; Sarwar MA; Baraka B; Shafiq T; Rao AR
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chimeric Antigen Receptors for the Tumour Microenvironment.
    Habib R; Nagrial A; Micklethwaite K; Gowrishankar K
    Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bright future or blind alley? CAR-T cell therapy for solid tumors.
    Zhang K; Chen H; Li F; Huang S; Chen F; Li Y
    Front Immunol; 2023; 14():1045024. PubMed ID: 36761757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CAR T Cell Therapy for Solid Tumors.
    Newick K; O'Brien S; Moon E; Albelda SM
    Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells.
    Aparicio C; Belver M; Enríquez L; Espeso F; Núñez L; Sánchez A; de la Fuente MÁ; González-Vallinas M
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies.
    Daei Sorkhabi A; Mohamed Khosroshahi L; Sarkesh A; Mardi A; Aghebati-Maleki A; Aghebati-Maleki L; Baradaran B
    Front Immunol; 2023; 14():1113882. PubMed ID: 37020537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.
    Badar T; Shah NN
    Curr Treat Options Oncol; 2020 Feb; 21(2):16. PubMed ID: 32025828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.